John J.P. Kastelein
QRx Pharma (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, Lipid metabolism and disorders, Cholesterol and Lipid Metabolism
Most-Cited Works
- → Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease(2017)8,806 cited
- → Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein(2008)6,560 cited
- → Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease(2005)3,485 cited
- → Effects of Torcetrapib in Patients at High Risk for Coronary Events(2007)3,113 cited
- → Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events(2015)2,268 cited
- → Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease(2011)1,937 cited
- → Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency(1999)